CytoDyn Revenue 2012-2025 | CYDY

CytoDyn revenue from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
CytoDyn Annual Revenue
(Millions of US $)
2025
2024
2023
2022 $0
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
CytoDyn Quarterly Revenue
(Millions of US $)
2025-11-30
2025-08-31
2025-05-31
2025-02-28
2024-11-30
2024-08-31
2024-05-31
2024-02-29
2023-11-30
2023-08-31
2023-05-31
2023-02-28
2022-11-30
2022-08-31
2022-05-31 $0
2022-02-28
2021-11-30 $0
2021-08-31 $0
2021-05-31
2021-02-28
2020-11-30
2020-08-31
2020-05-31
2020-02-29
2019-11-30
2019-08-31
2019-05-31
2019-02-28
2018-11-30
2018-08-31
2018-05-31
2018-02-28
2017-11-30
2017-08-31
2017-05-31
2017-02-28
2016-11-30
2016-08-31
2016-05-31
2016-02-29
2015-11-30
2015-08-31
2015-05-31
2015-02-28
2014-11-30
2014-08-31
2014-05-31
2014-02-28
2013-11-30
2013-08-31
2013-05-31
2013-02-28
2012-11-30
2012-08-31
2012-05-31
2012-02-29
2011-11-30
2011-08-31
2011-05-31
2011-02-28
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.314B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $89.845B 31.38
Takeda Pharmaceutical (TAK) Japan $56.639B 11.12
Zoetis (ZTS) United States $55.849B 19.99
BeOne Medicines - (ONC) Switzerland $38.053B 201.74
Sandoz Group AG (SDZNY) Switzerland $34.527B 0.00
Daiichi Sankyo, - (DSNKY) Japan $34.382B 17.12
United Therapeutics (UTHR) United States $20.621B 18.15
Merck (MKKGY) Germany $18.598B 11.47
Shionogi (SGIOY) Japan $18.477B 14.29
Neurocrine Biosciences (NBIX) United States $13.752B 33.00
Ionis Pharmaceuticals (IONS) United States $13.522B 0.00
IPSEN (IPSEY) France $13.306B 0.00
Orion OYJ (ORINY) Finland $11.502B 32.86
Summit Therapeutics (SMMT) United States $10.680B 0.00
Madrigal Pharmaceuticals (MDGL) United States $10.525B 0.00
Eisai (ESAIY) $8.400B 0.00
Ono Pharmaceutical (OPHLF) Japan $7.149B 17.10
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.947B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.643B 22.05
Crinetics Pharmaceuticals (CRNX) United States $4.576B 0.00
Indivior Pharmaceuticals (INDV) United States $4.307B 17.58
Stevanato Group S.p.A (STVN) Italy $4.285B 23.98
Corcept Therapeutics (CORT) United States $4.035B 43.59
NewAmsterdam Pharma (NAMS) Netherlands $3.635B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.164B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.939B 9.38
Hypermarcas (HYPMY) Brazil $2.793B 19.17
Dyne Therapeutics (DYN) United States $2.364B 0.00
Soleno Therapeutics (SLNO) United States $2.126B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $2.109B 0.00
Guardian Pharmacy Services (GRDN) United States $2.081B 40.08
Ocular Therapeutix (OCUL) United States $1.898B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.880B 22.28
Harrow (HROW) United States $1.706B 104.68
Ardelyx (ARDX) United States $1.701B 0.00
Enliven Therapeutics (ELVN) United States $1.602B 0.00
Definium Therapeutics (DFTX) United States $1.601B 0.00
Oruka Therapeutics (ORKA) United States $1.521B 0.00
Collegium Pharmaceutical (COLL) United States $1.483B 7.34
Amylyx Pharmaceuticals (AMLX) United States $1.427B 0.00
Relay Therapeutics (RLAY) United States $1.413B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.315B 78.00
Evotec AG (EVO) Germany $1.251B 0.00
Xeris Biopharma Holdings (XERS) United States $1.147B 0.00
Savara (SVRA) United States $1.050B 0.00
Theravance Biopharma (TBPH) United States $0.992B 41.66
Aktis Oncology (AKTS) United States $0.991B 0.00
Cronos Group (CRON) Canada $0.977B 0.00
ARS Pharmaceuticals (SPRY) United States $0.956B 0.00
Xencor (XNCR) United States $0.773B 0.00
Esperion Therapeutics (ESPR) United States $0.760B 0.00
KalVista Pharmaceuticals (KALV) United States $0.728B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.724B 17.11
Nektar Therapeutics (NKTR) United States $0.714B 0.00
Bioventus (BVS) United States $0.679B 13.91
Rigel Pharmaceuticals (RIGL) United States $0.603B 5.38
Altimmune (ALT) United States $0.555B 0.00
ProKidney (PROK) United States $0.520B 0.00
Lexeo Therapeutics (LXEO) United States $0.503B 0.00
Lyell Immunopharma (LYEL) United States $0.481B 0.00
4D Molecular Therapeutics (FDMT) United States $0.479B 0.00
Organogenesis (ORGO) United States $0.471B 0.00
Zevra Therapeutics (ZVRA) United States $0.471B 0.00
Aquestive Therapeutics (AQST) United States $0.468B 0.00
Siga Technologies (SIGA) United States $0.466B 6.38
Nature's Sunshine Products (NATR) United States $0.459B 27.33
Elite Pharmaceuticals (ELTP) United States $0.405B 0.00
USANA Health Sciences (USNA) United States $0.380B 10.62
Aclaris Therapeutics (ACRS) United States $0.367B 0.00
Akebia Therapeutics (AKBA) United States $0.366B 0.00
Protara Therapeutics (TARA) United States $0.336B 0.00
Aldeyra Therapeutics (ALDX) United States $0.306B 0.00
Cybin (HELP) Canada $0.292B 0.00
Journey Medical (DERM) United States $0.278B 0.00
Enlivex Therapeutics (ENLV) Israel $0.275B 0.00
Relmada Therapeutics (RLMD) United States $0.264B 0.00
Larimar Therapeutics (LRMR) United States $0.254B 0.00
Avalo Therapeutics (AVTX) United States $0.243B 0.00
OmniAb (OABI) United States $0.238B 0.00
Profound Medical (PROF) Canada $0.229B 0.00
Heron Therapeutics (HRTX) United States $0.222B 0.00
MediWound (MDWD) Israel $0.221B 0.00
Silence Therapeutics (SLN) United Kingdom $0.214B 0.00
Achieve Life Sciences (ACHV) Canada $0.210B 0.00
Context Therapeutics (CNTX) United States $0.208B 0.00
Minerva Neurosciences (NERV) United States $0.183B 0.00
Galectin Therapeutics (GALT) United States $0.182B 0.00
Surrozen (SRZN) United States $0.182B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.182B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
AleAnna (ANNA) United States $0.173B 0.00
VAXART, INC (VXRT) United States $0.150B 0.00
Century Therapeutics (IPSC) United States $0.146B 0.00
Unicycive Therapeutics (UNCY) United States $0.133B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.130B 0.00
Prelude Therapeutics (PRLD) United States $0.127B 0.00
Avita Medical (RCEL) United States $0.120B 0.00
Inhibikase Therapeutics (IKT) United States $0.119B 0.00
Karyopharm Therapeutics (KPTI) United States $0.112B 0.00
Korro Bio (KRRO) United States $0.109B 0.00
Cardiol Therapeutics (CRDL) Canada $0.107B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.106B 0.00
Vivani Medical (VANI) United States $0.096B 0.00
Pyxis Oncology (PYXS) United States $0.096B 0.00
Cassava Sciences (SAVA) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.091B 38.41
Incannex Healthcare (IXHL) Australia $0.087B 0.00
Assertio Holdings (ASRT) United States $0.075B 0.00
PolyPid (PYPD) Israel $0.069B 0.00
Gain Therapeutics (GANX) United States $0.062B 0.00
Rafael Holdings (RFL) United States $0.061B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.058B 0.00
Liminatus Pharma (LIMN) United States $0.055B 0.00
Dominari Holdings (DOMH) United States $0.055B 0.00
Fractyl Health (GUTS) United States $0.055B 0.00
PMV Pharmaceuticals (PMVP) United States $0.054B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.054B 44.88
Nutriband (NTRB) United States $0.053B 0.00
BioNxt Solutions (BNXTF) Canada $0.052B 0.00
Acrivon Therapeutics (ACRV) United States $0.050B 0.00
NRx Pharmaceuticals (NRXP) United States $0.050B 0.00
Lipocine (LPCN) United States $0.043B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Telomir Pharmaceuticals (TELO) United States $0.039B 0.00
Talphera (TLPH) United States $0.037B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
Lite Strategy (LITS) United States $0.035B 0.00
Plus Therapeutics (PSTV) United States $0.032B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.029B 0.00
Wellgistics Health (WGRX) United States $0.029B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.028B 0.00
TherapeuticsMD (TXMD) United States $0.025B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.019B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Scienture Holdings (SCNX) United States $0.017B 0.00
Cosmos Health (COSM) United States $0.016B 0.00
Klotho Neurosciences (KLTO) United States $0.016B 0.00
Iterum Therapeutics (ITRM) Ireland $0.015B 0.00
Citius Pharmaceuticals (CTXR) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Traws Pharma (TRAW) United States $0.014B 0.02
Inotiv (NOTV) United States $0.013B 0.00
Vyome Holdings (HIND) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
CASI Pharmaceuticals (CASI) China $0.012B 0.00
Tempest Therapeutics (TPST) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
BioVie (BIVI) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Ernexa Therapeutics (ERNA) United States $0.005B 0.00
Redhill Biopharma (RDHL) Israel $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Indaptus Therapeutics (INDP) United States $0.003B 0.00
Lyra Therapeutics (LYRA) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
China SXT Pharmaceuticals (SXTC) China $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
PainReform (PRFX) Israel $0.001B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00